title: Rebamipide to Manage Stomatopyrosis in Oral Submucous Fibrosis.
abstract: BACKGROUND
  Oral submucous fibrosis (OSF) causes progressive debilitating symptoms, such as oral burning sensation (stomatopyrosis) and limited mouth opening. The standard of care (SOC) protocol includes habit cessation, intralesional steroid and hyaluronidase injections, and mouth opening exercises. The objective of the study was to evaluate efficacy of rebamipide in alleviating burning sensation of the oral mucosa in OSF in comparison with SOC intralesional steroid injections.
  
  
  METHODS
  Twenty OSF patients were divided into two groups [rebamipide (100 mg TID for 21 days) and betamethasone (4 mg/mL biweekly for 4 weeks)] of 10 each by random sampling. Burning sensation was assessed every week for 1 month. Burning sensation scores were analyzed using repeated measures analysis of variance (ANOVA) and paired t-test.
  
  
  RESULTS
  Change in burning sensation score was significant (p < 0.05) in the first four visits. However, score between the 4th and 5th visit was not statistically significant (p > 0.05).
  
  
  CONCLUSIONS
  Our study has shown that rebamipide can be considered as an effective modality to manage burning sensation in patients suffering from OSF.
  
  
  CONCLUSIONS
  Considering stomatopyrosis and trismus as a major cause for inability to eat in OSF, use of newer adjunctive modalities, such as rebamipide will ease patients suffering and also encourage them to consume food.
authors.affiliation: Department of Oral and Maxillofacial Surgery, Manipal College of Dental Sciences, Manipal University, Mangaluru, Karnataka India.
authors.forename: Joanna
authors.initials: J
authors.lastname: Baptist
authors.affiliation: School of Dental Medicine, University of Colorado, Denver Colorado, USA, e-mail: shriju79@gmail.com.
authors.forename: Shrijana
authors.initials: S
authors.lastname: Shakya
authors.affiliation: Department of Oral and Maxillofacial Surgery, Manipal College of Dental Sciences, Manipal University, Mangaluru, Karnataka India.
authors.forename: Ravikiran
authors.initials: R
authors.lastname: Ongole
mesh_terms: D000328:Adult; D000368:Aged; D000409:Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001623:Betamethasone / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009914:Oral Submucous Fibrosis / Q000188:drug therapy* / Q000209:etiology; D010147:Pain Measurement; D011446:Prospective Studies; D015363:Quinolones / Q000627:therapeutic use*; D014030:Tobacco, Smokeless / Q000009:adverse effects
chemical_list: D000893:Anti-Inflammatory Agents; D015363:Quinolones; D001623:Betamethasone; C052785:rebamipide; D000409:Alanine
keywords: Betamethasone; Management; Oral submucous fibrosis Rebamipide.